Cramer Highlights Amgen's Repatha as Key Growth Engine Amid Cardiovascular Market Push

NEW YORK — Financial analyst Jim Cramer identified Amgen Inc.'s cholesterol-lowering drug Repatha as a primary catalyst for the biotechnology firm's future expansion, citing robust second-quarter sales figures and significant untapped market potential in the cardiovascular sector. Speaking on CNBC on September 1, 2026, Cramer contrasted Amgen's trajectory with that of rival Eli Lilly, positioning Repatha as a critical asset in an increasingly competitive landscape for lipid management therapies.

Amgen reported strong performance in its second quarter, driven largely by the sustained demand for Repatha. The drug, which targets low-density lipoprotein cholesterol to reduce the risk of heart attacks and strokes, has secured a substantial foothold in the United States healthcare market. Cramer noted that the sales momentum suggests Amgen is effectively capitalizing on the growing clinical emphasis on aggressive cholesterol management among high-risk patient populations.

The analyst's commentary came as the broader pharmaceutical industry navigates shifting dynamics in cardiovascular treatments. While Eli Lilly has garnered significant attention for its own portfolio of metabolic and weight-loss drugs, Cramer argued that Repatha remains a distinct growth driver due to its established efficacy and expanding indications. He emphasized that Amgen's ability to maintain market share against emerging competitors underscores the drug's enduring value proposition.

The cardiovascular market continues to evolve as new therapies enter clinical trials and regulatory review processes. Analysts are closely watching how Amgen leverages Repatha's current success to defend its position against potential generic competition and innovative biologics from other major players. The comparison between Amgen and Eli Lilly highlights the intense scrutiny investors place on companies with overlapping therapeutic areas, particularly as both firms vie for dominance in chronic disease management.

Cramer's assessment reflects a broader sentiment among market watchers that Amgen is well-positioned to translate its Q2 gains into long-term revenue stability. However, questions remain regarding the sustainability of this growth rate as patent cliffs loom and pricing pressures mount across the sector. The extent to which Repatha can continue to outpace competitors in a saturated market will depend on upcoming clinical data, regulatory approvals for new indications, and the company's strategic marketing initiatives.

As the third quarter unfolds, investors will be monitoring Amgen's ability to replicate its second-quarter success while navigating the complex interplay of drug pricing, reimbursement policies, and competitive threats. The rivalry between Amgen and Eli Lilly is expected to intensify as both companies seek to expand their footprints in the lucrative cardiovascular and metabolic disease sectors. Whether Repatha can maintain its status as a top-tier growth driver will likely hinge on these developing market conditions and the company's strategic responses to them.